Advanced Innovative Partners (AIP) empowers a global team of innovators from within and beyond the biopharmaceutical industry.
We tackle the most pressing challenges in healthcare today.
Our Team
Dr. Stanley Satz
Founder and Chairman
Dr. Stanley Satz
Founder and Chairman
Dr. Stanley Satz is a pre-eminent radiation physicist with over 40 years of experience, specializing in radiopharmaceuticals for targeted cancer therapy. His leadership spans from pharmaceuticals, defense and academia. Dr. Satz was awarded the first patent on accelerator production of Actinium-225 and a pioneer in the application of alpha emitting radioisotopes for medical use
Expertise and experience in nuclear physics at Advanced Innovative Partners (AIP) as Chief Scientific Officer
Founded Bio-Nucleonics, Inc., securing FDA approval for Strontium Chloride (Sr-89) to treat cancer bone pain
Former Professor at the University of Miami and Chairman of the Scientific Advisory Board at Florida Atlantic University
Ph.D. in Nuclear Physics
Roseanne Satz
Chief Executive Officer
Roseanne Satz
Chief Executive Officer
Ms. Roseanne Satz, Chief Executive Officer, and co-Founder is a seasoned businesswoman that has worked hard to make a difference in the world. Armed with degrees in both International Business and Marketing Management her credibility and aptitude for developing professional networks. She is a true entrepreneur engaged in multiple endeavors including serving as CEO and Co-Founder of Advanced Innovative Partners. She has served as a regulatory advisor and consultant for Johnson & Johnson as well several foreign and domestic pharmaceutical manufacturers. Ms. Satz successfully built a network of scientific experts, research organizations and manufacturing partners building a robust pipeline of diagnostics and therapeutics.
Colm King
Chief Financial Officer
Colm King
Chief Financial Officer
Mr. Colm King, Chief Financial Officer, has held executive finance leadership positions at PepsiCo, Inc., J.H. Cohn LLP, BDO Seidman, LLP, Peregrine Industries Inc., and Cavit Sciences, Inc. His roles included operating publicly traded and development stage biotech companies, structuring stock-based compensation plans, negotiating all contracts, developing internal control policies, conducting control& procedure evaluations, ensuring full compliance and complete disclosure, raising private and institutional capital and preparation of SEC filings.
Hamid Zolata, M.D., Ph.D.
Chief Medical Officer
Hamid Zolata, M.D., Ph.D.
Chief Medical Officer
Dr. Zolata, M.D, Ph.D., Chief Medical Officer, has extensive experience in radiopharmaceuticals and nuclear medicine including, but not limited to: Production, Quality Control, Preclinical evaluations; In vitro and In vivo, Tumor Targeting, Drug Delivery and Controlled Release, Molecular Imaging, IND Protocols, Therapy Planning, Quality Assurance, Regulatory affairs, Health Physics and Dosimetry Calculation, Clean Room and cGMP regulations
Sylvia Mergul, Ph.D
VP Clinical R&D
Sylvia Mergul, Ph.D
VP Clinical R&D
Dr. Mergui, Ph.D., Vice President of Clinal Research and Development, has extensive experience in materials science and nuclear medicine. She brings over 10 years of experience as a Professor of Electrical Engineering at Florida International University, along with prior research fellowship at the Nuclear Research Center CNRS in Strasbourg, France. She has made notable published contributions in material science and medical imaging research. Her publications are in the field of nuclear detectors, gamma imaging and sensor technology. She served as Research Director at Capintec/Mirion and as a consultant supporting the biotech industry. Dr. Mergui's credentials include certifications in Clinical Research (CRA) and in Clinical Data Management (CDM).
Brian Burnett. M.Sc.
Director, Drug Development
Brian Burnett. M.Sc.
Director, Drug Development
Mr.Greg Waterbury Vice President of Strategic Development and Operations is a Biologist with three decades of experience in life sciences operations in academia and with biotechnology companies. He specializes in start-ups, laboratory and production planning, R&D and facility process enablement/scale-up and consolidations. He authored a process patent and over a dozen publications in genomics, mutation detection and immunology. Greg has worked for investigators in Immunology and Genetics at Yale University and Howard Hughes Medical Institute. He held a global EHS project manager position at Life Technologies (now Thermo-Fisher), as well as key project management positions in biotech startups spun out of Yale University.
Greg Waterburry
VP Strategic Development
Greg Waterburry
VP Strategic Development
Mr. Brian Burnett, M. Sc, Director of Regulatory, Research and Regulatory Affairs, has focused on strategic development with considerable experience in cell and molecular cancer research, management of pilot production and process development scale-up in diagnostic and drug development in cGMP/GLP and CMC compliance. Mr. Burnett is also instrumental in developing INDs, BLAs, ANDAs, 505(b)2s, CBE-30s, NDAs, DMFs, formulated Orphan designation and Priority Review Voucher applications for submission to the FDA utilizing the eCTD web portal. He holds a Cell and Molecular Cancer Biochemistry honors bachelor’s degree.
Anne Harrington
Advisor - State Department
Paul Crowe
Radiopharmaceutical Advisor
Gerardo Morales
Board Advisor
Jim Self
Business Development Advisor
Thom Tulip, PhD.
Radiopharmaceutical Advisor